NPC(600713.SH)

Company Encyclopedia
View More
name
NPC
600713.SH
Nanjing Pharmaceutical Group Company Limited engages in the drug distribution businesses in China. It also involved in the wholesale and retail of medical device distribution; pharmaceutical logistics; and internet drug retail business. The company was formerly known as NanJing Pharmaceutical Company Limited and change its name to Nanjing Pharmaceutical Group Company Limited in December 2025. Nanjing Pharmaceutical Group Company Limited was founded in 1951 and is based in Nanjing, China.
391.68 B
600713.SHMarket value -Rank by Market Cap -/-

Financial Score

31/12/2025 Update
C
Health Care DistributorsIndustry
Industry Ranking13/25
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreC
    • ROE7.76%B
    • Profit Margin0.98%C
    • Gross Margin6.05%E
  • Growth ScoreC
    • Revenue YoY-0.16%D
    • Net Profit YoY-8.40%C
    • Total Assets YoY4.90%C
    • Net Assets YoY5.46%B
  • Cash ScoreB
    • Cash Flow Margin10154.79%A
    • OCF YoY-0.16%D
  • Operating ScoreA
    • Turnover1.62A
  • Debt ScoreE
    • Gearing Ratio76.62%E

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    NPC released its performance for the first three quarters, with a net profit attributable to the parent company of 402 million yuan, a year-on-year decrease of 9.03%

    According to the Zhitong Finance APP, NPC disclosed its third-quarter report for 2025. The company achieved a revenue of 41.135 billion yuan in the first three quarters, a year-on-year increase of 0.48%; the net profit attributable to shareholders was 402 million yuan, a year-on-year decrease of 9.03%; the net profit excluding non-recurring gains and losses was 371 million yuan, a year-on-year decrease of 14.78%; the basic earnings per share were 0.31 yuan

    Zhitong·
    SH
    600713
    +1.49%
    Zhitong·
    SH
    600713
    +1.49%

    NPC: Completed the repurchase of 17,999,900 shares

    NPC announced that the company has completed the repurchase of 17,999,900 shares, accounting for 1.38% of the total share capital, with an actual repurchase amount of 88.9221 million yuan, and a price range of 4.69 yuan/share to 5.22 yuan/share. This repurchase is intended for the implementation of the 2025 restricted stock incentive plan. The company first disclosed the repurchase plan on March 15, 2025, with an expected repurchase amount between 70 million yuan and 132 million yuan. The funds used for the repurchased shares come from the company's own funds or self-raised funds

    Zhitong·
    SH
    600713
    +1.49%
    Zhitong·
    SH
    600713
    +1.49%

    NPC: Will repay the principal and interest of 500 million yuan in ultra-short-term financing bonds

    NPC announced that it will pay the principal and interest of the fourth phase of the ultra-short-term financing bonds for the year 2025. The bond issuance amount is 500 million yuan, with an interest start date of May 22, 2025, and a term of 180 days. The interest rate for this period is 1.54%. The principal and interest payment date is November 18, 2025, with a total amount of 503.7973 million yuan to be repaid. The lead underwriters are Shanghai Pudong Development Bank and Bank of Nanjing

    Zhitong·
    SH
    600713
    +1.49%
    Zhitong·
    SH
    600713
    +1.49%

    NPC: The cumulative conversion amount of Nanjing Pharmaceutical's convertible bonds is 66,000 yuan

    NPC announced that the Nanjing Pharmaceutical convertible bonds will start converting into shares from July 1, 2025. As of September 30, 2025, the cumulative conversion amount is 66,000 yuan, resulting in 12,875 shares, accounting for 0.00098% of the issued shares. As of September 30, 2025, the amount of Nanjing Pharmaceutical convertible bonds that have not yet been converted is 1.081 billion yuan, accounting for 99.9939% of the total issuance

    Zhitong·
    SH
    600713
    +1.49%
    Zhitong·
    SH
    600713
    +1.49%

    NPC disclosed the progress of its centralized bidding repurchase of shares, having repurchased shares worth 80.2576 million yuan

    NPC disclosed its share repurchase progress, with the repurchase amount reaching 80.2576 million yuan. The repurchase plan was first announced on March 15, 2025, with an implementation period from March 14, 2025, to March 14, 2026. The expected repurchase amount is between 70 million yuan and 131.58 million yuan, mainly for employee stock ownership plans or equity incentives. As of September 30, 2025, the company has repurchased 16.299951 million shares, accounting for 1.25% of the total share capital

    Zhitong·
    SH
    600713
    +1.49%
    Zhitong·
    SH
    600713
    +1.49%
    © 2025 Longbridge｜Disclaimer